Navigation Links
Phase III Clinical Trial with 4-Month Long-Acting Formulation of,Triptorelin: Ipsen Decides Not to Perform Further Administration

ing to its pituitary receptor LHRH triggers the release of luteinizing hormone, a key factor for the regulation of reproductive function. Continuous administration of exogenous LHRH or its agonists such as triptorelin leads to a rapid desensitization of its pituitary receptor resulting in a paradoxical effect that translates into the suppression of gonadal steroids such as testosterone and estradiol. This chemically induced and reversible castration is of therapeutic benefit in the treatment of hormone sensitive tumours such as breast and prostate. Triptorelin is the active ingredient of Decapeptyl(R) and Diphereline(R) available as 1- and 3-month sustained release formulations registered for the treatment of advanced metastatic hormone-dependent prostate cancer.

About Ipsen

Ipsen is an innovation driven international specialty pharmaceutical group with over 20 products on the market and a total worldwide staff of nearly 4,000. The company's development strategy is based on a combination of products in targeted therapeutic areas (oncology, endocrinology and neuromuscular disorders) which are growth drivers, and primary care products which contribute significantly to its research financing. This strategy is also supported by an active policy of partnerships. The location of its four Research and Development centres (Paris, Boston, Barcelona, London) gives the Group a competitive edge in gaining access to leading university research teams and highly qualified personnel. In 2006, R&D expenditure was EUR 178.3 million, i.e. 20.7% of consolidated sales, which amounted to EUR 861.7 million while total revenues amounted to EUR 945.3 million (in IFRS). 700 people in R&D are dedicated to the discovery and development of innovative drugs for patient care. Ipsen's shares are traded on Segment A of Eurolist by Euronext(TM) (stock code: IPN, ISIN code: FR0010259150). Ipsen's shares are eligible to the "Systeme a Reglement Differe" ("SRD") and the Group is p
'"/>




Page: 1 2 3

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:12/22/2014)... LAWRENCE, Mass. , Dec. 22, 2014 /PRNewswire/ ... a leading manufacturer of innovative dialysis products, announced ... (FDA) has cleared its System One™ to perform ... sleeping, known as home nocturnal hemodialysis. NxStage,s® System ... cleared by the FDA for this indication. ...
(Date:12/22/2014)... LUXEMBOURG , Dec. 22, 2014  ConvaTec, a ... Paul Moraviec has been appointed Interim Chief Executive Officer ... Mr. Moraviec succeeds Ken Berger .  "The Board ... service in leading ConvaTec over the past three years," ... Board of Directors.  "We are confident that the company ...
(Date:12/22/2014)... , Dec, 22, 2014  Eiger BioPharmaceuticals ... 2a study of lonafarnib in patients with chronic ... conducted at the National Institutes of Health (NIH) ... .  The double-blinded, randomized, placebo-controlled, dose ascending study ... daily and 200 mg twice daily for 28 ...
Breaking Medicine Technology:NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3
... , a leading provider of therapeutic drug monitoring and ... today the appointment of David Cohen to Chief Operating ... responsible for new business analysis and development to expand ... Millennium,s legislative initiatives and community outreach programs. ...
... Pharmaceuticals, Inc. (Nasdaq: ISIS ) announces the following webcast:What: ... presented at ESCWhen: , Wednesday, September 1, 2010 at 4:00 ... Live on the Internet.  Simply log onto our Web site listed ... a replay of the webcast will be available for a limited ...
Cached Medicine Technology:Millennium Laboratories Announces New Chief Operating Officer David Cohen 2
(Date:12/24/2014)... As 2014 draws to a close, ... investing time and money into a new or tankless ... specializes in tankless and eco-friendly products or service. Greenstar ... heater in 2015 to research “green” and environmentally friendly ... Home Services specializes in eco-friendly and environmentally conscious ...
(Date:12/24/2014)... York (PRWEB) December 24, 2014 In ... the United States rode bicycles, hand cycles and recumbent ... D.C. in the inaugural CanAm Veterans’ Challenge . ... non-profit World T.E.A.M. Sports about this inspiring ride, is ... more than 50 full color photographs taken during the ...
(Date:12/24/2014)... 23, 2014 (HealthDay News) -- Each year, more than ... the United States occur because of extreme heat conditions, ... study finds that heat stroke is the leading cause ... as kidney failure and urinary tract infections, also put ... soar. The new data should help health care ...
(Date:12/24/2014)... -- Though most patients with obsessive-compulsive disorder (OCD) can ... percent to 20 percent have a form of the ... However, patients with this so-called "refractory OCD" do ... brain surgery that disables certain brain networks believed to ... patients most likely to benefit from the surgery, known ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 B. E. ... to healthcare providers, has been retained to lead a ... Tri-City Medical Center in Oceanside, Calif. The top ... B. E. Smith has recently placed more than 900 ... is a community owned, 397-bed, Gold Seal-approved, full-service acute-care ...
Breaking Medicine News(10 mins):Health News:Greenstar Home Services Offers Tankless Water Heater Advice to Local Homeowners 2Health News:New Commemorative Book Celebrates CanAm Veterans’ Challenge Bike Ride 2Health News:New Commemorative Book Celebrates CanAm Veterans’ Challenge Bike Ride 3Health News:Heat Stroke, Kidney Failure Help Drive Illnesses From Extreme Heat 2Health News:Scans May Spot People Who'll Benefit From Surgery for OCD 2Health News:Tri-City Medical Center Retains B. E. Smith to Recruit New Chief Compliance Officer 2Health News:Tri-City Medical Center Retains B. E. Smith to Recruit New Chief Compliance Officer 3
... Executive ... Chairman, SOUTH SAN ... company focused on the discovery,and development of drugs for major medical needs ... will step down today as President and Chief Executive Officer to,pursue another ...
... SAN DIEGO, Oct. 1 Amylin Pharmaceuticals,Inc. ... the U.S. Food and Drug,Administration (FDA) has ... pen-injector devices for administering SYMLIN(R),(pramlintide acetate) injection. ... dosing to improve mealtime glucose control. ...
... Presented at ERS 17th Annual Congress -, ... Inc.,today announced the submission of a pre-market approval ... (FDA) requesting regulatory,approval to market the Emphasys endobronchial ... Zephyr EBV is a minimally invasive and potentially,reversible ...
... have been homeless for any period of time after ... problems accessing health care than those with stable housing ... of Archives of Pediatrics & Adolescent Medicine, one of ... any period of time after leaving the foster care ...
... 1 Highlands Behavioral,Health System, a UHS facility, ... of Excellence for teens in crisis. The new ... Highlands Behavioral,Health ( http://www.highlandsbhs.com ) in Littleton, Colo. ... said the,Adolescent Center of Excellence represents an expansion ...
... was recently announced,as a silver winner in ... by,ComPsych Corporation. Concentra was selected based on ... achieved results. Concentra, a leader in ... commitment to better health and wellness among ...
Cached Medicine News:Health News:Renovis Announces Management Changes 2Health News:Renovis Announces Management Changes 3Health News:Renovis Announces Management Changes 4Health News:Renovis Announces Management Changes 5Health News:FDA Approves SYMLIN Pen-Injector Devices Offering Convenience and Accuracy for SYMLIN Use 2Health News:FDA Approves SYMLIN Pen-Injector Devices Offering Convenience and Accuracy for SYMLIN Use 3Health News:FDA Approves SYMLIN Pen-Injector Devices Offering Convenience and Accuracy for SYMLIN Use 4Health News:Emphasys Medical Announces PMA Submission for Bronchial Valve Therapy 2Health News:Emphasys Medical Announces PMA Submission for Bronchial Valve Therapy 3Health News:Poor health care access common among youth leaving foster system 2Health News:Poor health care access common among youth leaving foster system 3Health News:New Denver Area Program Developed For Teens in Crisis 2Health News:Concentra Honored With Silver Health at Work(SM) Award by ComPsych(R) Corp. 2
Polyester ribbons (3) impregnated with different OD values of conjugated Protein G...
Colloidal Gold Sol, 80 nm - 12 - 15 OD, 1 ml, Gold Sol Nanoparticles - not boiled, not centrifuged...
Colloidal Gold Sol, 20 nm - 12 - 15 OD, 1 ml, Gold Sol Nanoparticles - not boiled, not centrifuged...
... Pachymeter [i.e., PalmScan P2000] device is ... which incorporates A-mode pulsed-echo ultrasound,technology, and ... measure the corneal thickness (CT) and,epithelium ... P2000 includes two software user,interfaces; a ...
Medicine Products: